Pregabalin Capsule
Product Images NDC 71610-808

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-808). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71610-808-30 (71610 808 30)

Pregabalin 100 mg capsule bottle label for 30 capsules by Aphena Pharma Solutions - Tennessee, LLC. The label displays storage instructions, a barcode, the NDC 71610-808-30, manufacturing and packaging details, and warnings. The route of administration is oral.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure diagram of pregabalin, showing its molecular arrangement with an amino group and carboxylic acid group.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 25 mg, 100 mg, and 200 mg taken three times a day, compared with placebo. The vertical axis represents the percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph comparing the percent of patients with pain improvement between Pregabalin 100 mg three times a day and placebo groups. The x-axis represents percent improvement in pain from baseline, while the y-axis shows the percent of patients improved. Two lines illustrate differences in response rates between Pregabalin and placebo across various levels of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph displaying the percent of patients improved on the vertical axis against percent improvement in pain from baseline on the horizontal axis. The graph compares four groups: Pregabalin 300 mg two times a day, Pregabalin 150 mg two times a day, Pregabalin 75 mg two times a day, and placebo, illustrating varying levels of pain improvement among these groups.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, with lines indicating their respective trends across different pain improvement percentages.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph showing percent of patients improved over a ranging baseline measure. Three lines represent Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The x-axis marks percent improvement from 0 to 100, and the y-axis marks percent of patients improved from 0 to 100.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar graph showing responder rates (%) for two clinical studies labeled Study E1 and Study E3. The graph compares placebo and varying doses of pregabalin (50, 150, 300, 600 mg per day) administered twice daily (BID) in Study E1, and placebo versus 300 mg BID and 600 mg three times daily (TID) doses in Study E3. Responder rates increase with higher doses in both studies.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line chart depicting seizure reduction (median percentage change from baseline) versus dose in mg/day. The chart compares results from three studies (E1 BID, E2 TID, E3 BID, E3 TID) with significant p-values indicated at various doses, including 0 dose (placebo), 150 mg/day, 300 mg/day, and 600 mg/day, showing increased seizure reduction with higher doses.*

FDA Label Image

Figure 9 (Pregabalin 09)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. The graph compares four groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo. The lines indicate patient improvement trends across different pain improvement percentages.*

FDA Label Image

Figure 10 (Pregabalin 10)

A survival curve graph comparing the estimated percentage of subjects without LTR over days for Pregabalin versus Placebo. The x-axis represents days, ranging from 0 to 180, and the y-axis shows the estimated percentage of subjects without LTR, from 0% to 100%. The solid line represents Pregabalin, and the dashed line represents Placebo.*

FDA Label Image

Figure 11 (Pregabalin 11)

A line graph showing the percent of subjects improved from baseline to week 12 using the Brief Overall Clinical Functioning (BOCF) scale. The x-axis represents the percent improved from baseline, ranging from greater than 0 to 100%. The y-axis represents the percent of subjects improved, ranging from 0 to 100%. Two lines compare Pregabalin and Placebo, with Pregabalin consistently showing higher percentages of subjects improved across the improvement range.*

FDA Label Image

Figure 12 (Pregabalin 12)

A line graph comparing the percent of subjects improved from baseline to week 16 BOCF for Pregabalin versus Placebo. The x-axis shows the percent improved, and the y-axis shows the percent of subjects improved, with Pregabalin and Placebo represented by separate lines.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.